Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

• Status: Completed
• Trial end date: 2015-12-01

Summary

The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin, irinotecan, and Erbitux treatments.

• Phase: Phase 1

Details

• Lead Sponsor: Jennerex Biotherapeutics
• Collaborator: Samsung Medical Center
• Treatments: Molgramostim; Sargramostim